2025-522468-34-00招募中1 期
Phase I clinical trial evaluating the safety, tolerability, and absorption of a topical product containing latanoprost acid in healthy participants.
Bioresearch Pharma S.A.2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2026年2月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Maciej Wierzbicki
Scientific
Bioresearch Pharma S.A.
研究点 (2)
Loading locations...
相似试验
招募中
1 期
Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of intravenous single ascending doses of IM-250 in healthy volunteers.Herpes simplex virus encephalitis2025-523146-27-00Innovative Molecules GmbH30
招募中
1 期
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77
招募中
1 期
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.2025-522243-17-00Philogen S.p.A.96
招募中
1 期
A trial to investigate the safety and pharmacokinetics of GRT6019 in healthy male participants.2025-523587-20-00Gruenenthal GmbH24
招募中
1 期
A first-in-human trial to evaluate safety, tolerability, and pharmacokinetics of single and multiple oral doses of Debio 1453P in healthy adults2024-519328-26-01Debiopharm International S.A.88